8 completed, 1 unknown, 1 withdrawn. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Fungemia: new trials by email Literature Review of Fungemia trials Research Report on Fungemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia Interferon Gamma-1B - Candidemia | Phase 2 | Completed | Radboud University Medical Center | 65 | 2022-03-31 | 2026-06-22 |
| An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris APX001 - Candidemia, Invasive Candidiases | Phase 2 | Completed | Basilea Pharmaceutica | 9 | 2019-12-13 | 2025-09-16 |
| An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia APX001 - Candidemia | Phase 2 | Completed | Basilea Pharmaceutica | 21 | 2018-10-03 | 2025-09-16 |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension CD101, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 207 | 2016-07-26 | 2020-12-08 |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis SCY-078, Fluconazole, Micafungin - Mycoses, Candidiasis, Invasive | Phase 2 | Completed | Scynexis, Inc. | 27 | 2014-09-01 | 2024-06-25 |
| Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients Caspofungin - Fungemia, Mycoses | Phase 2 | Unknown | Azienda Ospedaliera di Padova | 38 | 2009-05-01 | 2012-07-18 |
| Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection voriconazole (Vfend) - Candidiasis, Candidemia | Phase 2 | Completed | Pfizer | 40 | 2008-12-01 | 2011-01-28 |
| A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia hLF1-11, Placebo - Candidaemia | Phase 1 / Phase 2 | Withdrawn | AM-Pharma | 2008-07-01 | 2015-06-30 | |
| The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis. Anidulafungin, VER002 - Candidiasis | Phase 2 | Completed | Pfizer | 120 | 2001-08-01 | 2008-10-21 |
| Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis FK463 - Candidiasis | Phase 2 | Completed | Astellas Pharma Inc | 75 | 1999-02-27 | 2018-01-10 |
Candidemia (9) · Candidiasis (4) · Candidiasis, Invasive (4) · Mycoses (3) · Invasive Fungal Infections (1) · Torulopsis (1)
Bacterial Infections and Mycoses (10) · Infections (10) · Inflammation (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Sepsis (10) · Systemic Inflammatory Response Syndrome (10) · Invasive Fungal Infections (9) · Mycoses (7) · Candidiasis (5) · Candidiasis, Invasive (5)
Caspofungin (2) · Fluconazole (2) · Micafungin (2) · Anidulafungin (1) · Injections (1) · Voriconazole (1) · ibrexafungerp (1) · interferon gamma-1b (1) · lactoferrin (1-11), human (1)
Basilea Pharmaceutica (2) · Pfizer (2) · AM-Pharma (1) · Astellas Pharma Inc (1) · Azienda Ospedaliera di Padova (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Radboud University Medical Center (1) · Scynexis, Inc. (1)
United States (6) · Germany (4) · Italy (3) · Spain (3) · Belgium (2) · Greece (2) · Netherlands (2) · Romania (2) · Austria (1) · Bulgaria (1) · Canada (1) · El Salvador (1) · France (1) · Guatemala (1) · Honduras (1)
Marc Engelhardt (2) · Daniele Neri, MD (1) · David Angulo, MD (1) · Professor P.E. Verweij, MD, PhD (1) · Taylor Sandison, MD MPH (1) · Umberto Cillo, MD (1)
PMID 32955088, PMID 37022196, PMID 37596890, PMID 38008099, PMID 38502709, PMID 39468640, PMID 39529079, PMID 41940006
2008 (1), 2015 (1)